| Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy YG Puranik, AK Birnbaum, SE Marino, G Ahmed, JC Cloyd, RP Remmel, ... Pharmacogenomics 14 (1), 35-45, 2013 | 134 | 2013 |
| A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer JJ Yang, J Fang, YQ Shu, JH Chang, GY Chen, JX He, W Li, XQ Liu, ... Investigational New Drugs 39, 477-487, 2021 | 56 | 2021 |
| OA 09.03 TATTON Ph Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI M Ahn, J Han, L Sequist, BC Cho, JS Lee, S Kim, W Su, C Tsai, JC Yang, ... Journal of Thoracic Oncology 12 (11), S1768, 2017 | 50 | 2017 |
| SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell … GR Oxnard, M Cantarini, P Frewer, G Hawkins, J Peters, P Howarth, ... Journal of Clinical Oncology 37 (15_suppl), TPS9119-TPS9119, 2019 | 41 | 2019 |
| Inhibition of Pseudomonas aeruginosa PAO1 adhesion to and invasion of A549 lung epithelial cells by natural extracts GF Ahmed, WF Elkhatib, AM Noreddin Journal of infection and public health 7 (5), 436-444, 2014 | 35 | 2014 |
| A pharmacotherapy capstone course to advance pharmacy students’ clinical documentation skills JM Conway, GF Ahmed American journal of pharmaceutical education 76 (7), 134, 2012 | 35 | 2012 |
| OA 09.06 A phase Ib trial of savolitinib plus gefitinib for chinese patients with EGFR-mutant MET-amplified advanced NSCLC J Fang, Y Shu, J Chang, G Chen, J He, W Li, X Liu, N Yang, C Zhou, ... Journal of Thoracic Oncology 12 (11), S1769, 2017 | 24 | 2017 |
| Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy GF Ahmed, RC Brundage, SE Marino, JC Cloyd, IE Leppik, PB Pennell, ... The Journal of Clinical Pharmacology 53 (3), 276-284, 2013 | 23 | 2013 |
| Pharmacokinetics and saturable absorption of gabapentin in nursing home elderly patients GF Ahmed, SPR Bathena, RC Brundage, IE Leppik, JM Conway, ... The AAPS journal 19, 551-556, 2017 | 20 | 2017 |
| Pharmacokinetic–pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers GF Ahmed, SE Marino, RC Brundage, SVS Pakhomov, IE Leppik, ... British Journal of Clinical Pharmacology 79 (5), 820-830, 2015 | 18 | 2015 |
| A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity RDO Jones, M Grondine, A Borodovsky, M San Martin, M DuPont, ... British Journal of Pharmacology 178 (3), 600-613, 2021 | 9 | 2021 |
| Pharmacodynamics of moxifloxacin versus vancomycin against biofilms of methicillin-resistant Staphylococcus aureus and epidermidis in an in vitro model AH Salem, WF Elkhatib, GF Ahmed, AM Noreddin Journal of Chemotherapy 22 (4), 238-242, 2010 | 9 | 2010 |
| Savolitinib±osimertinib in Japanese patients with advanced solid malignancies or EGFRm NSCLC: Ph1b TATTON Part C K Yoh, T Hirashima, H Saka, T Kurata, Y Ohe, T Hida, A Mellemgaard, ... Targeted Oncology 16 (3), 339-355, 2021 | 8 | 2021 |
| A randomized, double‐blind, placebo‐and positive‐controlled, three‐way crossover study in healthy participants to investigate the effect of savolitinib on the QTc interval T Sahota, CD Dota, T Vik, W Yan, RB Verheijen, S Walker, Y Li, ... Clinical Pharmacology in Drug Development 10 (5), 521-534, 2021 | 7 | 2021 |
| P1. 01-134 SAVANNAH: phase II trial of osimertinib+ savolitinib in EGFR-mutant, MET-driven advanced NSCLC, following prior osimertinib M Ahn, M Cantarini, P Frewer, G Hawkins, J Peters, P Howarth, G Ahmed, ... Journal of Thoracic Oncology 14 (10), S415-S416, 2019 | 6 | 2019 |
| FRI0156 pharmacokinetics of ABT-122, a dual TNF-and IL-17A-targeted DVD-IG™, after single dosing in healthy volunteers and multiple dosing in subjects with rheumatoid arthritis GF Ahmed, S Goss, P Jiang, H Mansikka, RJ Padley, AA Othman Annals of the rheumatic diseases 74 (Suppl 2), 479-479, 2015 | 6 | 2015 |
| Parent and metabolite concentration-QT modeling to evaluate QT-interval prolongation at savolitinib therapeutic doses S Schalkwijk, T Sahota, RB Verheijen, AR Harmer, GF Ahmed The AAPS Journal 23, 1-10, 2021 | 4 | 2021 |
| Application of Pharmacokinetics/Pharmacodynamics (PK/PD) in Designing Effective Antibiotic Treatment Regimens GF Ahmed, AM Noreddin Readings in Advanced Pharmacokinetics: Theory, Methods and Applications, 388, 2012 | 4 | 2012 |
| The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration. W Awni, S Pilari, G Ahmed, P Noertersheuser Arthritis and Rheumatism 65, S214-S214, 2013 | 3 | 2013 |
| Adalimumab in combination with high and low dose-methotrexate in rheumatoid arthritis patients with inadequate response to methotrexate: pharmacokinetic results from the MUSICA … G Ahmed, SL Goss, CE Klein, N Mozaffarian, GS Kaeley, W Awni ARTHRITIS AND RHEUMATISM 65, S623-S624, 2013 | 3 | 2013 |
Ayman NoreddinAhram Canadian UniversityVerified email at acu.edu.eg
